CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) Director Leonard E. Post sold 1,000 shares of CG Oncology stock in a transaction on Monday, January 13th. The shares were sold at an average price of $29.66, for a total value of $29,660.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Leonard E. Post also recently made the following trade(s):
- On Friday, December 6th, Leonard E. Post sold 1,000 shares of CG Oncology stock. The shares were sold at an average price of $34.54, for a total value of $34,540.00.
CG Oncology Price Performance
NASDAQ:CGON opened at $27.97 on Wednesday. The business’s fifty day moving average price is $32.28 and its 200 day moving average price is $34.25. CG Oncology, Inc. has a 12 month low of $25.77 and a 12 month high of $50.23.
Institutional Trading of CG Oncology
Several institutional investors have recently modified their holdings of the stock. State Street Corp grew its position in shares of CG Oncology by 73.0% in the 3rd quarter. State Street Corp now owns 1,700,653 shares of the company’s stock valued at $64,166,000 after buying an additional 717,722 shares during the last quarter. Ally Bridge Group NY LLC boosted its stake in CG Oncology by 50.5% in the third quarter. Ally Bridge Group NY LLC now owns 263,266 shares of the company’s stock valued at $9,933,000 after acquiring an additional 88,390 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of CG Oncology by 114.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 379,664 shares of the company’s stock worth $14,325,000 after purchasing an additional 202,262 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of CG Oncology by 876.9% during the third quarter. BNP Paribas Financial Markets now owns 26,660 shares of the company’s stock worth $1,006,000 after purchasing an additional 23,931 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C lifted its holdings in shares of CG Oncology by 811.9% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 433,540 shares of the company’s stock valued at $13,687,000 after purchasing an additional 386,000 shares during the last quarter. Hedge funds and other institutional investors own 26.56% of the company’s stock.
Analysts Set New Price Targets
CGON has been the topic of several research reports. Bank of America reissued a “buy” rating and set a $65.00 price target on shares of CG Oncology in a research report on Tuesday, October 8th. UBS Group began coverage on shares of CG Oncology in a research note on Thursday, October 24th. They issued a “buy” rating and a $60.00 price target for the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $66.00 price objective on shares of CG Oncology in a research note on Friday, December 6th. TD Cowen assumed coverage on CG Oncology in a research note on Tuesday, January 7th. They set a “buy” rating for the company. Finally, HC Wainwright restated a “buy” rating and set a $75.00 price target on shares of CG Oncology in a report on Friday, January 10th. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, CG Oncology currently has an average rating of “Buy” and a consensus price target of $63.88.
Check Out Our Latest Analysis on CG Oncology
About CG Oncology
CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.
Read More
- Five stocks we like better than CG Oncology
- What is the NASDAQ Stock Exchange?
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- What is a SEC Filing?
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- The How And Why of Investing in Oil Stocks
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.